Kavaliauskas, Povilas
Gu, Yiyou
Hasin, Naushaba
Graf, Karen T.
Alqarihi, Abdullah http://orcid.org/0000-0003-4408-6398
Shetty, Amol C. http://orcid.org/0000-0001-8790-7649
McCracken, Carrie
Walsh, Thomas J.
Ibrahim, Ashraf S. http://orcid.org/0000-0003-3787-8530
Bruno, Vincent M. http://orcid.org/0000-0003-1683-2015
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI110820, AI141360, AI063503, AI110820, AI141360)
Article History
Received: 21 June 2023
Accepted: 12 June 2024
First Online: 20 June 2024
Competing interests
: A.S.I. owns shares in Vitalex Biosciences, a start-up company that is developing immunotherapies and diagnostics for mucormycosis. T.J.W. has received grants for experimental and clinical antimicrobial pharmacology, therapeutics, and diagnostics to his institution from Amplyx, Astellas, Gilead, Lediant, Merck, Scynexis, Shionogi, T2 Biosystems, Viosera; and has served as a consultant to Abbott, Astellas, Karyopharm, Leadiant, Partner Therapeutics, Scynexis, Shionogi, Statera, and T2 Biosystems. The remaining authors declare no competing interests.